Literature DB >> 23426849

Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume.

C J Simpkin1, V A Morgan, S L Giles, S F Riches, C Parker, N M deSouza.   

Abstract

OBJECTIVE: To establish whether T2 relaxation and apparent diffusion coefficient (ADC) in normal prostate and tumour are related and to investigate the effects of glandular compression from an enlarged transition zone (TZ) on peripheral zone (PZ) T2 and ADC by correlating them with the peripheral zone fractional volume (PZFV).
METHODS: 48 consecutive patients prospectively underwent multiecho T2 weighted (T2W) (echo times 20, 40, 60, 80, 100 ms) and diffusion-weighted (b=0, 100, 300, 500, 800 s mm(-2)) endorectal MRI. In 43 evaluable patients, single slice whole PZ, TZ and tumour (focal hypointense signal on T2W images in a biopsy-positive octant) regions of interest were transferred to T2 and ADC maps by slice matching. T2 and ADC values were correlated, and PZ values were correlated with PZFV.
RESULTS: T2 and ADC values were significantly different among groups [T2 mean±standard deviation (SD) PZ, 149±49 ms; TZ, 125±26 ms; tumour, 97±23 ms; PZ vs TZ, p=0.002; PZ vs tumour, p<0.0001; TZ vs tumour, p<0.0001; ADC×10(-6) mm(2) s(-1) mean±SD PZ, 1680±215; TZ, 1478±139; tumour, 1030±205; p<0.0001]. Significant positive correlations existed between T2 and ADC for PZ, TZ, PZ and TZ together, but not for tumour (r=0.515, p<0.0001; r=0.300, p=0.03; r=0.526, p<0.0001; and r=0.239, p=0.32, respectively). No significant correlation existed between PZFV and PZ T2 (r=0.10, p=0.5) or ADC (r=0.03, p=0.8).
CONCLUSION: The correlation between T2 and ADC that exists in normal prostate is absent in tumour. PZ compression by an enlarged TZ does not alter PZ T2 or ADC to affect tumour-PZ contrast. ADVANCES IN KNOWLEDGE: Microstructural features of tumours alter diffusivity independently of their effects on T2 relaxation.

Entities:  

Mesh:

Year:  2013        PMID: 23426849      PMCID: PMC3635787          DOI: 10.1259/bjr.20120469

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  29 in total

1.  Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups.

Authors:  T A Stamey; T S Sözen; C M Yemoto; J E McNeal
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

2.  MR depiction of zonal anatomy of the prostate at 1.5 T.

Authors:  F G Sommer; J E McNeal; C L Carrol
Journal:  J Comput Assist Tomogr       Date:  1986 Nov-Dec       Impact factor: 1.826

3.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging.

Authors:  Huadong Miao; Hiroshi Fukatsu; Takeo Ishigaki
Journal:  Eur J Radiol       Date:  2006-11-07       Impact factor: 3.528

4.  High-field quantitative transverse relaxation time, magnetization transfer and apparent water diffusion in experimental rat brain tumour.

Authors:  L Lemaire; F Franconi; J P Saint-Andre; V G Roullin; P Jallet; J J Le Jeune
Journal:  NMR Biomed       Date:  2000-05       Impact factor: 4.044

5.  Diagnostic utility of DTI in prostate cancer.

Authors:  Bengi Gürses; Neslihan Tasdelen; Faruk Yencilek; N Ozgür Kılıckesmez; Turgut Alp; Zeynep Fırat; M Selami Albayrak; Aziz M Uluğ; A Nevzat Gürmen
Journal:  Eur J Radiol       Date:  2010-02-06       Impact factor: 3.528

6.  Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance.

Authors:  Stijn W T P J Heijmink; Jurgen J Fütterer; Thomas Hambrock; Satoru Takahashi; Tom W J Scheenen; Henkjan J Huisman; Christina A Hulsbergen-Van de Kaa; Ben C Knipscheer; Lambertus A L M Kiemeney; J Alfred Witjes; Jelle O Barentsz
Journal:  Radiology       Date:  2007-05-10       Impact factor: 11.105

7.  Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy.

Authors:  Liang Wang; Yousef Mazaheri; Jingbo Zhang; Nicole M Ishill; Kentaro Kuroiwa; Hedvig Hricak
Journal:  Radiology       Date:  2007-11-16       Impact factor: 11.105

8.  Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.

Authors:  V A Morgan; S Kyriazi; S E Ashley; N M DeSouza
Journal:  Acta Radiol       Date:  2007-07       Impact factor: 1.990

9.  Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.

Authors:  Yousef Mazaheri; Amita Shukla-Dave; Hedvig Hricak; Samson W Fine; Jingbo Zhang; Gloria Inurrigarro; Chaya S Moskowitz; Nicole M Ishill; Victor E Reuter; Karim Touijer; Kristen L Zakian; Jason A Koutcher
Journal:  Radiology       Date:  2008-02       Impact factor: 11.105

10.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.

Authors:  Masoom A Haider; Theodorus H van der Kwast; Jeff Tanguay; Andrew J Evans; Ali-Tahir Hashmi; Gina Lockwood; John Trachtenberg
Journal:  AJR Am J Roentgenol       Date:  2007-08       Impact factor: 3.959

View more
  9 in total

1.  Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Authors:  Alice C Yu; Chaitra Badve; Lee E Ponsky; Shivani Pahwa; Sara Dastmalchian; Matthew Rogers; Yun Jiang; Seunghee Margevicius; Mark Schluchter; William Tabayoyong; Robert Abouassaly; Debra McGivney; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-02-10       Impact factor: 11.105

2.  A novel alternative to classify tissues from T 1 and T 2 relaxation times for prostate MRI.

Authors:  Jorge Zavala Bojorquez; Stéphanie Bricq; François Brunotte; Paul M Walker; Alain Lalande
Journal:  MAGMA       Date:  2016-05-09       Impact factor: 2.310

3.  Magnetic resonance fingerprinting in prostate cancer before and after contrast enhancement.

Authors:  Young Sub Lee; Moon Hyung Choi; Young Joon Lee; Dongyeob Han; Dong-Hyun Kim
Journal:  Br J Radiol       Date:  2021-08-20       Impact factor: 3.039

Review 4.  MR fingerprinting of the prostate.

Authors:  Wei-Ching Lo; Ananya Panda; Yun Jiang; James Ahad; Vikas Gulani; Nicole Seiberlich
Journal:  MAGMA       Date:  2022-04-13       Impact factor: 2.533

5.  Creatine CEST MRI for Differentiating Gliomas with Different Degrees of Aggressiveness.

Authors:  Kejia Cai; Rong-Wen Tain; Xiaohong Joe Zhou; Frederick C Damen; Alessandro M Scotti; Hari Hariharan; Harish Poptani; Ravinder Reddy
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

6.  Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.

Authors:  Ananya Panda; Gregory OʼConnor; Wei Ching Lo; Yun Jiang; Seunghee Margevicius; Mark Schluchter; Lee E Ponsky; Vikas Gulani
Journal:  Invest Radiol       Date:  2019-08       Impact factor: 6.016

7.  Incorporating Oxygen-Enhanced MRI into Multi-Parametric Assessment of Human Prostate Cancer.

Authors:  Heling Zhou; Rami R Hallac; Qing Yuan; Yao Ding; Zhongwei Zhang; Xian-Jin Xie; Franto Francis; Claus G Roehrborn; R Douglas Sims; Daniel N Costa; Ganesh V Raj; Ralph P Mason
Journal:  Diagnostics (Basel)       Date:  2017-08-24

8.  Two-centre comparative experimental study of biparametric MRI at 3.0 T with and without endorectal coil using kiwifruit (Actinidia deliciosa) as a phantom for human prostate.

Authors:  Sophie Murer; Juergen Scheidler; Ulrike L Mueller-Lisse; Marissa Helling; Michael Scherr; Ullrich G Mueller-Lisse
Journal:  Eur Radiol Exp       Date:  2019-08-14

9.  Multicenter Repeatability and Reproducibility of MR Fingerprinting in Phantoms and in Prostatic Tissue.

Authors:  Wei-Ching Lo; Leonardo Kayat Bittencourt; Ananya Panda; Yun Jiang; Junichi Tokuda; Ravi Seethamraju; Clare Tempany-Afdhal; Verena Obmann; Katherine Wright; Mark Griswold; Nicole Seiberlich; Vikas Gulani
Journal:  Magn Reson Med       Date:  2022-06-17       Impact factor: 3.737

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.